Engineering of optogenetic devices for biomedical applications in mammalian synthetic biology

Gene‐ and cell‐based therapies are the next frontiers in the field of medicine. Both are transformative and innovative therapies; however, a lack of safety data limits the translation of such promising technologies to the clinic. Improving the safety and promoting the clinical translation of these therapies can be achieved by tightly regulating the release and delivery of therapeutic outputs. In recent years, the rapid development of optogenetic technology has provided opportunities to develop precision‐controlled gene‐ and cell‐based therapies, in which light is introduced to precisely and spatiotemporally manipulate the behaviour of genes and cells. This review focuses on the development of optogenetic tools and their applications in biomedicine, including photoactivated genome engineering and phototherapy for diabetes and tumours. The prospects and challenges of optogenetic tools for future clinical applications are also discussed.

Abstract licence: CC BY-ND

1. 53.

   Near-infrared photoactivatable control of Ca2+ signaling and optogenetic immunomodulation · 2015

2. 61.

   CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity · 2016

3. 69.

   Optogenetic protein clustering through fluorescent protein tagging and extension of CRY2 · 2017

4. 104.

   Optophysiology: Illuminating cell physiology with optogenetics · 2022

104 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.